Share on StockTwits

RXi Pharmaceuticals Corp (NASDAQ:RXII) CEO Geert Cauwenbergh purchased 2,000 shares of the company’s stock in a transaction that occurred on Thursday, June 19th. The stock was purchased at an average cost of $2.98 per share, with a total value of $5,960.00. Following the completion of the purchase, the chief executive officer now directly owns 26,100 shares of the company’s stock, valued at approximately $77,778. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

RXII has been the subject of a number of recent research reports. Analysts at Laidlaw initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, June 2nd. They set a “buy” rating and a $8.00 price target on the stock. Separately, analysts at Wainwright initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, May 5th. They set a “buy” rating and a $9.00 price target on the stock. Finally, analysts at HC Wainwright initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, May 5th. They set a “buy” rating and a $9.00 price target on the stock.

RXi Pharmaceuticals Corp (NASDAQ:RXII) traded up 1.02% during mid-day trading on Friday, hitting $2.97. 5,605 shares of the company’s stock traded hands. RXi Pharmaceuticals Corp has a 52-week low of $2.55 and a 52-week high of $6.84. The stock’s 50-day moving average is $3.01 and its 200-day moving average is $3.94. The company’s market cap is $41.7 million.

RXi Pharmaceuticals Corp (NASDAQ:RXII) last announced its earnings results on Wednesday, May 14th. The company reported ($0.32) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.31) by $0.01. On average, analysts predict that RXi Pharmaceuticals Corp will post $-0.89 earnings per share for the current fiscal year.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) is a development-stage company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.